$ITGR

Integer Shares Rally On $127 Per Share KKR Offer - Integer Holdings (NYSE:ITGR)

Integer Holdings (ITGR) said its board unanimously approved KKR’s offer to acquire the company for $127 per share, a 51.8% premium to its April 29, 2026 close. Integer withdrew prior guidance after reporting Q2 adjusted EPS of $1.60 on revenue of $464.1 million. The deal is expected to close by year-end.

Original reporting
Published Aug 3, 2026, 2:56 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 5:46 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Integer Shares Rally On $127 Per Share KKR Offer - Integer Holdings (NYSE:ITGR) — source image
Decision brief

The 30-second read

$ITGRBullishHigh
01

Why it matters

The $127 per share offer, unanimous board approval, and guidance withdrawal materially change ITGR’s valuation framework from standalone earnings to deal completion probability and timing, with the $127 level acting as a key ceiling.

02

Market read

Traders should focus on deal certainty, the vote process, and the gap between the current price and the $127 offer as a measure of implied completion risk.

03

What to watch

The article notes guidance withdrawal and canceled earnings call, which can reduce near-term fundamental visibility and increase uncertainty for non-deal-arb holders.

Relevance 9/10Novelty 9/10Timing: today, premarket trading and deal-arb repricing around the $127 offer

Background

Integer Holdings is a medical device components manufacturer with one segment and multiple product lines, now facing a board-approved acquisition offer.

Company-level read

Ticker impact

$ITGRBullishHigh confidence
Context

Integer Holdings agreed to be acquired for $127 per share, a 51.8% premium, and withdrew guidance ahead of the deal vote.

Expected impact

Near-term upside is capped by the $127 offer price, with elevated volatility possible as traders price deal certainty and timing to year-end.

Evidence & confidence

The article discloses the offer price, premium, board recommendation, and guidance withdrawal, which directly affect expected value and risk for ITGR holders and deal-arb traders.

Market effects

Medical device component suppliers may see deal-arb interest if acquisition premiums remain attractive, but the article is company-specific.

No specific regional macro or regulatory driver beyond the US-focused company and global operations mention.

Limited, as the disclosed catalyst is a single-company acquisition offer and not a cross-border policy or sector shock.

Counterpoint

Even with a premium, deal completion risk (customary closing conditions) can keep the stock below the offer price, making downside possible if regulatory or financing hurdles emerge.

Key entities

  • Integer Holdings

    Subject of the acquisition offer at $127 per share, with guidance withdrawn and earnings call canceled.

  • KKR

    Named acquirer in the proposed transaction for Integer.

Related articles

$ITGRHighAI 9/10

What Integer's Deal Means for Minnesota's Med Device Industry

Integer Holdings, a major medical device manufacturer, is being acquired by KKR for $5.7B. Integer supplies components to companies like Abbott, Boston Scientific, and Medtronic. The deal may impact Minnesota's med-tech industry, where Integer has significant operations. KKR's acquisition could lead to consolidation in the sector, with potential implications for competition and pricing. Integer reported $1.8B in revenue last year.

$KKRHighAI 9/10

KKR to Acquire Integer Holdings in $5.7 Bn All-Cash Deal

KKR will acquire medical device outsourcing company Integer Holdings in an all-cash deal valued at about $5.7 billion, paying $127 per share and assuming Integer’s outstanding debt, according to the companies. The offer implies a 4.78% premium to Integer’s Friday close. Integer shares rose 2.4% premarket. KKR said it will expand its healthcare portfolio.

$SUPNMed

Biotech funding rises 75% year-over-year, Braveheart surges

Macquarie said global biotech funding for the year through Aug. 7 rose 75% YoY, driven by IPOs up 235% and follow-ons up 138%. The XBI biotech index gained 7% in the week to Aug. 7. Braveheart Bio’s upsized IPO raised $382.5M and shares jumped 66%. Curium agreed to buy Lantheus for up to $8B, and Supernus and Indivior plan an all-stock merger.

$KKRHighAI 9/10

KKR to take Integer private for $5.7B

KKR agreed to buy Integer Holdings for about $5.7B in an all-cash deal, taking Integer private. The transaction is expected to close before year-end, subject to regulatory approvals and shareholder support. Integer stockholders would receive about $127 per share, a 51%+ premium to April 29. Integer reported $464M Q2 sales, down 2.6%.